User menu

Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.

Bibliographic reference Charette, Nicolas ; De Saeger, Christine ; Horsmans, Yves ; Leclercq, Isabelle ; Starkel, Peter. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.. In: Cell Death & Disease, Vol. 4, no.epub, p. e471 (2013)
Permanent URL http://hdl.handle.net/2078.1/136289
  1. El-Serag Hashem B., Hepatocellular Carcinoma, 10.1056/nejmra1001683
  2. Hanahan Douglas, Weinberg Robert A., Hallmarks of Cancer: The Next Generation, 10.1016/j.cell.2011.02.013
  3. Fabregat Isabel, Dysregulation of apoptosis in hepatocellular carcinoma cells, 10.3748/wjg.15.513
  4. Ashkenazi Avi, Herbst Roy S., To kill a tumor cell: the potential of proapoptotic receptor agonists, 10.1172/jci34359
  5. Schattenberg Jorn Markus, Schuchmann Marcus, Galle Peter Robert, Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways : Cell death and hepatocarcinogenesis, 10.1111/j.1440-1746.2010.06582.x
  6. Zhang Lidong, Fang Bingliang, Mechanisms of resistance to TRAIL-induced apoptosis in cancer, 10.1038/sj.cgt.7700792
  7. Calvisi Diego F., Ladu Sara, Gorden Alexis, Farina Miriam, Lee Ju-Seog, Conner Elizabeth A., Schroeder Insa, Factor Valentina M., Thorgeirsson Snorri S., Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma, 10.1172/jci31457
  8. Villanueva Augusto, Chiang Derek Y., Newell Pippa, Peix Judit, Thung Swan, Alsinet Clara, Tovar Victoria, Roayaie Sasan, Minguez Beatriz, Sole Manel, Battiston Carlo, van Laarhoven Stijn, Fiel Maria I., Di Feo Analisa, Hoshida Yujin, Yea Steven, Toffanin Sara, Ramos Alex, Martignetti John A., Mazzaferro Vincenzo, Bruix Jordi, Waxman Samuel, Schwartz Myron, Meyerson Matthew, Friedman Scott L., Llovet Josep M., Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma, 10.1053/j.gastro.2008.08.008
  9. Calvisi Diego F., Ladu Sara, Gorden Alexis, Farina Miriam, Conner Elizabeth A., Lee Ju–Seog, Factor Valentina M., Thorgeirsson Snorri S., Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC, 10.1053/j.gastro.2006.01.006
  10. Tam Ka Ho, Yang Zhen Fan, Lau Chi Keung, Lam Chi Tat, Pang Roberta W.C., Poon Ronnie T.P., Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma, 10.1016/j.canlet.2008.08.018
  11. Sahu Ravi P., Batra Sanjay, Kandala Prabodh K., Brown Thomas L., Srivastava Sanjay K., The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines, 10.1007/s00280-010-1463-1
  12. Marom M., Haklai R., Ben-Baruch G., Marciano D., Egozi Y., Kloog Y., Selective Inhibition of Ras-dependent Cell Growth by Farnesylthiosalisylic Acid, 10.1074/jbc.270.38.22263
  13. Tsimberidou Apostolia Maria, Rudek Michelle A., Hong David, Ng Chaan S., Blair Jessica, Goldsweig Howard, Kurzrock Razelle, Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors, 10.1007/s00280-009-1027-4
  14. da Silva Morais Alain, Saliez Alain, Leclercq Isabelle, Horsmans Yves, Stärkel Peter, Inhibition of the Ras oncoprotein reduces proliferation of hepatocytesin vitroandin vivoin rats, 10.1042/cs20070152
  15. Schneider-Merck T., Borbath I., Charette N., De Saeger C., Abarca J., Leclercq I., Horsmans Y., Stärkel P., The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats, 10.1016/j.ejca.2009.04.014
  16. Stärkel Peter, Charette Nicolas, Borbath Ivan, Schneider-Merck Tanja, De Saeger Christine, Abarca Jorge, Leclercq Isabelle, Horsmans Yves, Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: Association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis, 10.1002/mc.20849
  17. Charette Nicolas, De Saeger Christine, Lannoy Valérie, Horsmans Yves, Leclercq Isabelle, Stärkel Peter, Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition, 10.1186/1476-4598-9-256
  18. Bopp Stephanie K, Lettieri Teresa, Comparison of four different colorimetric and fluorometric cytotoxicity assays in a zebrafish liver cell line, 10.1186/1471-2210-8-8
  19. Blum R., Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis, 10.1158/1535-7163.mct-06-0193
  20. Satoh T., Okamoto I., Miyazaki M., Morinaga R., Tsuya A., Hasegawa Y., Terashima M., Ueda S., Fukuoka M., Ariyoshi Y., Saito T., Masuda N., Watanabe H., Taguchi T., Kakihara T., Aoyama Y., Hashimoto Y., Nakagawa K., Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors, 10.1158/1078-0432.ccr-08-1946
  21. Kelley Robert F., Totpal Klara, Lindstrom Stephanie H., Mathieu Mary, Billeci Karen, DeForge Laura, Pai Roger, Hymowitz Sarah G., Ashkenazi Avi, Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling, 10.1074/jbc.m410660200
  22. Hotte S. J., Hirte H. W., Chen E. X., Siu L. L., Le L. H., Corey A., Iacobucci A., MacLean M., Lo L., Fox N. L., Oza A. M., A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies, 10.1158/1078-0432.ccr-07-1416
  23. Wakelee H. A., Patnaik A., Sikic B. I., Mita M., Fox N. L., Miceli R., Ullrich S. J., Fisher G. A., Tolcher A. W., Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors, 10.1093/annonc/mdp292
  24. Falschlehner Christina, Schaefer Uta, Walczak Henning, Following TRAIL’s path in the immune system, 10.1111/j.1365-2567.2009.03058.x
  25. Mita A. C., Mita M. M., Nawrocki S. T., Giles F. J., Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics, 10.1158/1078-0432.ccr-08-0746
  26. Ye Chao-Ping, Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma, 10.3748/wjg.13.6264
  27. Dai De-Jian, Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells, 10.3748/wjg.v11.i2.193
  28. Biran Anat, Brownstein Michael, Haklai Ronit, Kloog Yoel, Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy, 10.1002/ijc.25367
  29. Kanwar Jagat R., Kamalapuram Sishir K., Kanwar Rupinder K., Targeting survivin in cancer: the cell-signalling perspective, 10.1016/j.drudis.2011.04.001
  30. Sarthy A. V., Morgan-Lappe S. E., Zakula D., Vernetti L., Schurdak M., Packer J. C.L., Anderson M. G., Shirasawa S., Sasazuki T., Fesik S. W., Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells, 10.1158/1535-7163.mct-06-0560
  31. Blum R., Elkon R., Yaari S., Zundelevich A., Jacob-Hirsch J., Rechavi G., Shamir R., Kloog Y., Gene Expression Signature of Human Cancer Cell Lines Treated with the Ras Inhibitor Salirasib (S-Farnesylthiosalicylic Acid), 10.1158/0008-5472.can-06-4287
  32. Goldberg L, Israeli R, Kloog Y, FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice, 10.1038/cddis.2012.24
  33. Chen K.-F., Tai W.-T., Liu T.-H., Huang H.-P., Lin Y.-C., Shiau C.-W., Li P.-K., Chen P.-J., Cheng A.-L., Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3, 10.1158/1078-0432.ccr-09-3389
  34. Livak Kenneth J., Schmittgen Thomas D., Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method, 10.1006/meth.2001.1262